12th August, 2024

Corporate Relationship Department Manager – Listing

M/s. BSE Ltd M/s. National Stock Exchange of India Ltd
Dalal Street, For, “Exchange Plaza”, Bandra Kurla Complex
Mumbai 400001 Bandra East, Mumbai 400051

Scrip Code: 524816 Scrip Code: NATCOPHARM

Dear Sir / Madam,

Sub: - Q1 FY25 Investor Presentation

Please find enclosed herewith the Investor Presentation for the Quarter ended June 30, 2024.

Thanking you

Yours faithfully
For NATCO Pharma Limited
Chekuri Venkat Digitally signed by Chekuri Venkat
Ramesh
Ramesh Date: 2024.08.12 18:32:44 +05'30'

Ch. Venkat Ramesh

Company Secretary &
Compliance Officer

Encl: as above
Earnings Presentation
Q1FY25
 Disclaimer
THIS PRESENTATION (PRESENTATION) IS NOT AN OFFER TO SELL ANY SECURITIES OR A SOLICITATION TO BUY ANY SECURITIES OF NATCO PHARMA LIMITED OR ITS SUBSIDIARIES OR JOINT VENTURES (TOGETHER, THE “COMPANY”).
The material that follows is a Presentation of general background information about the Company’s activities as at the date of the Presentation or as otherwise indicated. It is information given in summary form and does not purport to be complete
and it cannot be guaranteed that such information is true and accurate. This Presentation has been prepared by and is the sole responsibility of the Company. By accessing this Presentation, you are agreeing to be bound by the trading restrictions.
It is for general information purposes only and should not be considered as a recommendation that any investor should subscribe / purchase the Company shares.
This Presentation includes statements that are, or may be deemed to be, “forward-looking statements”. These forward-looking statements can be identified by the use of forward- looking terminology, including the terms “believes”, “estimates”,
“anticipates”, “projects”, “expects”, “intends”, “may”, “will”, “seeks” or “should” or, in each case, their negative or other variations or comparable terminology, or by discussions of strategy, plans, aims, objectives, goals, future events or intentions.
These forward-looking statements include all matters that are not historical facts. They appear in a number of places throughout this Presentation and include statements regarding the Company’s intentions, beliefs or current expectations concerning,
amongst other things, its results or operations, financial condition, liquidity, prospects, growth, strategies and the industry in which the Company operates.
By their nature, forward-looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future. Forward-looking statements are not guarantees of future performance
including those relating to general business plans and strategy of the Company, its future outlook and growth prospects, and future developments in its businesses and its competitive and regulatory environment. No representation, warranty or
undertaking, express or implied, is made or assurance given that such statements, views, projections or forecasts, if any, are correct or that the objectives of the Company will be achieved. There are some important factors that could cause material
differences to Company’s actual results. These include (i) our ability to successfully implement our strategy (ii) our growth and expansion plans (iii) changes in regulatory norms applicable to the Company (iv) technological changes (v) investment and
business income (vi) cash flow projections etc. (vii) exposure to market as well as other risks.
The Company, as such, makes no representation or warranty, express or implied, as to, and does not accept any responsibility or liability with respect to, the fairness, accuracy, completeness or correctness of any information or opinions contained
herein. The information contained in this Presentation, unless otherwise specified is only current as of the date of this Presentation. The Company assumes no responsibility to publicly amend, modify or revise any forward-looking statements based on
any subsequent development, information or events, or otherwise. Unless otherwise stated in this Presentation, the information contained herein is based on management information and estimates.
Any opinions expressed in this presentation are subject to change without notice. The presentation should not be construed as legal, tax, investment or other advice. None of the Company or any of its affiliates, advisers or representatives accepts
any liability whatsoever for any loss howsoever arising from any information presented or contained in this presentation. The information contained in this presentation has not been independently verified. Furthermore, no person is authorized to
give any information or make any representation which is not contained in, or is inconsistent with, this presentation. Any such extraneous or inconsistent information or representation, if given or made, should not be relied upon as having been
authorized by or on behalf of the Company. Further, past performance is not necessarily indicative of future results.
This document is just a Presentation for information purposes and private circulation only and is not intended to be a “prospectus” or “offer document” or a “private placement offer letter” (as defined or referred to, as the case may be, under the
Companies Act, 2013). It is clarified that this Presentation is not intended to be a document offering for subscription or sale of any securities or inviting offers from the Indian public (including any section thereof) or from persons residing in any other
jurisdiction including the United States for the subscription to or sale of any securities including the equity shares of the Company or any of its subsidiaries. No part of it should form the basis of or be relied upon in connection with any investment
decision or any contract or commitment to purchase or subscribe for any securities. None of the Company’s securities may be offered or sold in the United States without registration under the U.S. Securities Act of 1933, as amended, except
pursuant to an exemption from registration there from.
This document has not been and will not be reviewed or approved by a regulatory authority in India or by any stock exchange in India. This presentation is confidential and this presentation or any part thereof should not be used or relied upon by
any other party or for any other purpose and should not be copied, reproduced, recirculated, redistributed, published in any media, website or otherwise, in any form or manner, in part or as a whole, without the express consent in writing of the
Company. Any unauthorized use, disclosure or public dissemination of information contained herein is prohibited. The distribution of this presentation in certain jurisdictions may be restricted by law. Accordingly, any persons in possession of the
aforesaid should inform themselves about and observe any such restrictions.

NATCO Pharma Limited – Earnings Presentation – Q1FY25

 Table of Contents

1 Q1FY25 Key Business & Consolidated Financial Highlights

2 Financial Summary

3 Product Portfolio & Pipeline

Natco Pharma Limited – Earnings Presentation – Q1FY25

 1
Q1FY25 Key Business &
Consolidated Financial
Highlights

Natco Pharma Limited – Earnings Presentation – Q1FY25

Q1FY25 – Key Business & Consolidated Financial Highlights

Total Revenue stood at INR 14,107 mn| Pharma Export Formulations at INR 12,101 mn | Domestic Formulations Revenue at INR 1,022 mn

Earnings Before Interest Tax Depreciation and Amortization stood at INR 8,529 mn for Q1FY25

Profit after tax for Q1FY25 was at INR 6,685 mn

Basic and Diluted EPS for FY25 is INR 37.32 per share

Filed 3 ANDAs with the USFDA

The Board of Directors has declared interim dividend of INR 3 per equity share of INR 2 each.

Note: EBITDA and EBITDA Margin includes other income

5
NATCO Pharma Limited – Earnings Presentation – Q1FY25
Q1FY25 – Quarterly Performance
Revenue Breakup (INR mn) Revenue Breakup (%) – Q1FY25
1% 3% 3%
Revenue Division Q1FY25 Q1FY24 Q4FY24 7%

API Revenue 392 751 500

Formulation

Formulation – Exports (incl profit share,

license income, export service income & 12,101 8,842 9,549 86%
Subsidiaries) Export Formulation Domestic Formulation
Crop Health Science API
Other operating and non-operating income
Formulation – Domestic 1,022 1,324 524
Revenue Breakup (%) – FY24
Formulations Total Revenue 13,123 10,166 10,073
6% 4%
3%
Crop Health Sciences 156 447 (3.7)
9%

Other Operating & Non - operating

436 238 534
incomes

Consolidated Total Revenue 14,107 11,602 11,103

78%
Export Formulation Domestic Formulation
Crop Health Science API
Other operating and non-operating income 6
NATCO Pharma Limited – Earnings Presentation – Q1FY25
 2

Financial Summary

Natco Pharma Limited – Earnings Presentation – Q1FY25

Consolidated Profit & Loss Statement
Profit & Loss Statement (INR Million) Q1FY25 Q1FY24 Q4FY24

Total Revenue 14,107 11,602 11,103

Total Expenses (before finance cost and depreciation) 5,578 6,125 5,710

Earnings before interest, tax, depreciation and amortization (EBITDA) 8,529 5,477 5,393

EBITDA Margin* (%) 60.5% 47.2% 48.6%

Finance cost 52 42 62

Depreciation 441 435 555

Profit before tax (PBT) 8,036 5,000 4,776

Tax 1,351 797 913

Profit after tax (PAT) 6,685 4,203 3,863

PAT Margin (%) 47.4% 36.2% 34.8%

Reported Earnings per share (EPS) INR – Basic and Diluted 37.32 23.26 21.56

*includes other income

8
NATCO Pharma Limited – Earnings Presentation – Q1FY25
 3

Key Product Pipeline

Natco Pharma Limited – Earnings Presentation – Q1FY25

Key Product Pipeline - USA

28 Para IVs in the pipeline 13 Approved (either tentative or fully)

Key Sole FTFs (Para IV) in the pipeline Key Para IV products in the pipeline

Therapeutic Therapeutic
Key Brand Molecule Segment / Primary Key Brand Molecule
Segment / Primary Indication
Indication
Eliquis Apixaban Anticogulant
Tracleer Bosentan (32mg) Anti-hypertensive
Ozempic Semaglutide pen Diabetes
Kyprolis Carfilzomib (10mg) Cancer/Multiple Myeloma

Imbruvica Ibrutinib (tablet) Cancer/Leukaemia Pomalyst Pomalidomide Cancer/Multiple Myeloma

Zydelig Idelalisib Cancer Lonsurf Trifluridine/Tipracil Metastatic colorectal cancer

Lynparza Olaparib Ovarian/Breast Cancer Advanced soft-tissue sarcoma/
Yondelis Trabectedin
ovarian cancer
Ozempic Semaglutide pen (8mg/3ml & 2 mg/3ml) Diabetes
Calquence Acalabrutinib Cancer/Blood
Balversa Erdafitinib Bladder Cancer

Wegovy Semaglutide (all strengths) Weight Loss Nurtec Rimegepant Migraine

Note: Data as of June 30, 2024

10
NATCO Pharma Limited – Earnings Presentation – Q1FY25
Earnings Call Details – Q1FY25

The Earnings call to discuss the operational and financial performance of the company with Mr. Rajeev Nannapaneni,
Director and Chief Executive Officer and Mr. Rajesh Chebiyam, Executive Vice President, Crop Health Sciences will be
held at 11 AM on 13/08/2024.

Details of the Earnings call:

• Date: 13th August 2024
• Time: 11 AM IST
• Dial-in-Numbers: (+91 22) 62801222 / 71158123
• Pre-register using the link:
https://services.choruscall.in/DiamondPassRegistration/register?confirmationNumber=1966275&linkSecurityString=cb680a02b

11
NATCO Pharma Limited – Earnings Presentation – Q1FY25
 Thank You
Contact:
Rajeev Menon – Investor Relations
Rajesh Chebiyam – EVP, Crop Health Sciences
[email protected] / [email protected]

040-23546323

https://twitter.com/pharma_natco

https://www.linkedin.com/company/natcopharma